Elyse G. Seltzer
Corporate Officer/Principal bei Yale University
Aktive Positionen von Elyse G. Seltzer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Yale University | Corporate Officer/Principal | - | - |
Karriereverlauf von Elyse G. Seltzer
Ehemalige bekannte Positionen von Elyse G. Seltzer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
UROGEN PHARMA LTD. | Technik-/Wissenschafts-/F&E-Leiter | 12.12.2017 | 01.04.2020 |
Corporate Officer/Principal | 01.04.2020 | 01.05.2023 | |
NABRIVA THERAPEUTICS PLC | Technik-/Wissenschafts-/F&E-Leiter | 23.06.2017 | 30.09.2017 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Technik-/Wissenschafts-/F&E-Leiter | 04.05.2015 | 01.09.2017 |
GSK PLC | Corporate Officer/Principal | 01.09.2009 | 01.04.2015 |
TENGION, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2006 | 01.08.2009 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Corporate Officer/Principal | - | - |
JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Corporate Officer/Principal | - | - |
Ausbildung von Elyse G. Seltzer
University of Pennsylvania | Undergraduate Degree |
New York University School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Vereinigtes Königreich | 2 |
Österreich | 2 |
Operativ
Corporate Officer/Principal | 6 |
Chief Tech/Sci/R&D Officer | 4 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 9 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
TENGION, INC. | Health Technology |
JOHNSON & JOHNSON | Health Technology |
GSK PLC | Health Technology |
NABRIVA THERAPEUTICS PLC | Health Technology |
UROGEN PHARMA LTD. | Health Technology |
Private Unternehmen | 3 |
---|---|
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
- Börse
- Insiders
- Elyse G. Seltzer
- Erfahrung